Nexalin Technology, Inc. (NXL)

Nexalin Technology will go public soon, but the exact IPO date is still unknown.
Stock Price: $5.00 - $7.00
Current IPO price range
Chart not available yet
Data will show when the stock starts trading.
Market Cap38.43M
Revenue (ttm)152,570
Net Income (ttm)-5.94M
Shares Out6.41M
EPS (ttm)-0.93
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About NXL

Nexalin Technology designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. We have developed an easy-to-administer medical device — referred to as Gen-1 – that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. This device emits our original waveform at 4 milliamps during treatment and is classified by the FDA as a Class II device. While this device had been cleared by the FDA to treat anxie...

IndustryHealth Care
Founded2010
CEOMark White
Employees2
Stock ExchangeNASDAQ
Ticker SymbolNXL
Full Company Profile

Financial Performance

In 2020, NXL's revenue was $242,914, an increase of 17.13% compared to the previous year's $207,383. Losses were -$3.40 million, -32.22% less than in 2019.

Financial Statements

News

Nexalin Technology, Inc. IPO Registration Document (S-1)

Nexalin Technology, Inc. has filed to go public with an IPO on the NASDAQ.

4 months ago - SEC